25 April 2008 in Circulation Research
Cardiac hypertrophy is promoted by adrenergic overactivation and can progress to heart failure, a leading cause of mortality worldwide. Although cAMP is among the most well-known signaling molecules produced by β-adrenergic receptor stimulation, its mechanism of action in cardiac hypertrophy is not fully understood. The identification of Epac (exchange protein directly activated by cAMP) proteins as novel sensors for cAMP has broken the dogma surrounding cAMP and protein kinase A. However, their role and regulation in the mature heart remain to be defined. Here, we show that cardiac hypertrophy induced by thoracic aortic constriction increases Epac1 expression in rat myocardium. Adult ventricular myocytes isolated from banded animals display an exaggerated cellular growth in response to Epac activation. At the molecular level, Epac1 hypertrophic effects are independent of its classic effector, Rap1, but rather involve the small GTPase Ras, the phosphatase calcineurin, and Ca 2+ /calmodulin-dependent protein kinase II. Importantly, we find that in response to β-adrenergic receptor stimulation, Epac1 activates Ras and induces adult cardiomyocyte hypertrophy in a cAMP-dependent but protein kinase A–independent manner. Knockdown of Epac1 strongly reduces β-adrenergic receptor–induced hypertrophic program. Finally, we report for the first time that Epac1 is mainly expressed in human heart as compared with Epac2 isoform and is increased in heart failure. Taken together, our data demonstrate that the guanine nucleotide exchange factor Epac1 contributes to the hypertrophic effect of β-adrenergic receptor in a protein kinase A–independent fashion and may, therefore, represent a novel therapeutic target for the treatment of cardiac disorders.
30 August 2007 in The Journal of Physiology
MFMaría Fernández‐Velasco
+6
CAMP is a powerful second messenger whose known general effector is protein kinase A (PKA). The identification of a cAMP binding protein, Epac, raises the question of its role in Ca2+ signalling in cardiac myocytes. In this study, we analysed the effects of Epac activation on Ca2+ handling by using confocal microscopy in isolated adult rat cardiomyocytes. [Ca2+]i transients were evoked by electrical stimulation and Ca2+ sparks were measured in quiescent myocytes. Epac was selectively activated by the cAMP analogue 8‐(4‐chlorophenylthio)‐2′‐O‐methyladenosine‐3′,5′‐cyclic monophosphate (8‐CPT). Patch‐clamp was used to record the L‐type calcium current (ICa), and Western blot to evaluate phosphorylated ryanodine receptor (RyR). [Ca2+]i transients were slightly reduced by 10 μm 8‐CPT (F/F0: decreased from 4.7 ± 0.5 to 3.8 ± 0.4, P < 0.05), an effect that was boosted when cells were previously infected with an adenovirus encoding human Epac. ICa was unaltered by Epac activation, so this cannot explain the decreased [Ca2+]i transients. Instead, a decrease in the sarcoplasmic reticulum (SR) Ca2+ load underlies the decrease in the [Ca2+]i transients. This decrease in the SR Ca2+ load was provoked by the increase in the SR Ca2+ leak induced by Epac activation. 8‐CPT significantly increased Ca2+ spark frequency (Ca2+ sparks s−1 (100 μm)−1: from 2.4 ± 0.6 to 6.9 ± 1.5, P < 0.01) while reducing their amplitude (F/F0: 1.8 ± 0.02 versus 1.6 ± 0.01, P < 0.001) in a Ca2+/calmodulin kinase II (CaMKII)‐dependent and PKA‐independent manner. Accordingly, we found that Epac increased RyR phosphorylation at the CaMKII site. Altogether, our data reveal a new signalling pathway by which cAMP governs Ca2+ release and signalling in cardiac myocytes.
9 December 2005 in Circulation Research
CAMP is one of the most important second messenger in the heart. The discovery of Epac as a guanine exchange factor (GEF), which is directly activated by cAMP, raises the question of the role of this protein in cardiac cells. Here we show that Epac activation leads to morphological changes and induces expression of cardiac hypertrophic markers. This process is associated with a Ca 2+ -dependent activation of the small GTPase, Rac. In addition, we found that Epac activates a prohypertrophic signaling pathway, which involves the Ca 2+ sensitive phosphatase, calcineurin, and its primary downstream effector, NFAT. Rac is involved in Epac-induced NFAT dependent cardiomyocyte hypertrophy. Blockade of either calcineurin or Rac activity blunts the hypertrophic response elicited by Epac indicating these signaling molecules coordinately regulate cardiac gene expression and cellular growth. Our results thus open new insights into the signaling pathways by which cAMP may mediate its biological effects and identify Epac as a new positive regulator of cardiac growth.
1 August 2011 in Cellular Signalling
1 January 2012 in Journal of Molecular and Cellular Cardiology
25 October 2009 in Pflügers Archiv - European Journal of Physiology